Search results for "hematopoietic stem cell transplantation"

showing 10 items of 290 documents

Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice

2015

Reactivation of human cytomegalovirus (HCMV) can cause severe disease in recipients of hematopoietic stem cell transplantation. Although preclinical research in murine models as well as clinical trials have provided 'proof of concept' for infection control by pre-emptive CD8 T-cell immunotherapy, there exists no predictive model to experimentally evaluate parameters that determine antiviral efficacy of human T cells in terms of virus control in functional organs, prevention of organ disease, and host survival benefit. We here introduce a novel mouse model for testing HCMV epitope-specific human T cells. The HCMV UL83/pp65-derived NLV-peptide was presented by transgenic HLA-A2.1 in the conte…

Human cytomegaloviruslcsh:Immunologic diseases. Allergymedicine.medical_treatmentT cellImmunologyCell- and Tissue-Based TherapyCytomegalovirusEpitopes T-LymphocyteMice TransgenicHematopoietic stem cell transplantationHuman leukocyte antigenMice SCIDBiologyMicrobiologyViral Matrix ProteinsMice Inbred NODVirologyHLA-A2 AntigenGeneticsmedicineCytotoxic T cellAnimalsHumansMolecular Biologylcsh:QH301-705.5ImmunotherapyViral Loadmedicine.diseaseMice Inbred C57BLDisease Models Animalmedicine.anatomical_structurelcsh:Biology (General)ImmunologyCytomegalovirus InfectionsParasitologylcsh:RC581-607Viral loadCD8Research ArticlePLoS Pathogens
researchProduct

Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoie…

2004

Transplantation Centers using human cytomegalovirus (HCMV) antigenemia-based preemptive therapy will need to replace in the near future the antigenemia assay with a more standardized and automatable assay, such as a molecular assay quantifying HCMV DNA in blood (DNAemia). Thus, in view of replacing antigenemia with clinically safe cutoff values, DNAemia levels corresponding to antigenemia cutoffs guiding HCMV preemptive therapy were determined retrospectively in solid organ and hematopoietic stem cell transplant recipients (HSCTR) using an "in-house" quantitative PCR (QPCR) method. Since preemptive therapy had prevented appearance of HCMV disease in all patients tested, DNA cutoffs determin…

Human cytomegalovirusmedicine.medical_specialtymedicine.medical_treatmentCytomegalovirusHematopoietic stem cell transplantationAntiviral AgentsPolymerase Chain ReactionOrgan transplantationPostoperative ComplicationsPredictive Value of TestsBetaherpesvirinaeVirologyPositive predicative valuemedicineHumansCutoffViremiaAntigens ViralRetrospective StudiesAntiviral Agentbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesCytomegaloviruOrgan Transplantationbiology.organism_classificationmedicine.diseaseVirologyTransplantationInfectious DiseasesPredictive value of testsCytomegalovirus InfectionsDNA Viralbusiness
researchProduct

P046 Deconstructing HLA-C mismatch in hematopoietic stem cell transplantation

2016

Contrary to other HLA loci, allele vs antigen mismatches in HLA-C appear to differentially impact HSCT outcome. Aim of this study was to investigate the independent role of other factors characterizing a patient’s HLA-C non-shared allele, in HSCT outcome as well as their distribution in allele vs antigen mismatched cases. 288 9/10 HLA-C mismatched unrelated transplant pairs, were additionally genotyped by sequence based typing for rs9264942(C/T) and rs67384697(ins/del), which are considered surrogate markers of HLA-C expression levels. A proxy MFI model as previously described (Petersdorf et al., Blood 2014), was also implemented in the analysis. All patient non-shared alleles were characte…

Incidence (epidemiology)medicine.medical_treatmentImmunologyGeneral MedicineHuman leukocyte antigenHematopoietic stem cell transplantationBiologyEpitopeHLA-CAntigenGenotypeImmunologymedicineImmunology and AllergyAlleleHuman Immunology
researchProduct

A PCR-Based Assay for the Detection of Langerhans-Cell Chimerism after Allogeneic Stem Cell Transplantation.

2006

Abstract Early acute GVHD of the skin frequently occurs in patients after allogeneic hematopoietic stem cell transplantation. Although T cell depletion reduces the incidence and severity, it does not completely prevent skin GVHD. This leads to a prolonged need for immunosuppressive medication in a significant number of patients. For the induction of acute GVHD, the stimulation of donor T cells by residing host antigen presenting cells such as Langerhans cells of the skin (LCs) plays a central role. The absence of donor T cells after depletion, however, seems to hamper an early switch of LCs from host to donor origin. Therefore, the monitoring of LC chimerism is of great interest. We and oth…

Langerhans cellintegumentary systemLangerinbiologymedicine.medical_treatmentT cellImmunologyCell BiologyHematologyHuman leukocyte antigenHematopoietic stem cell transplantationBiochemistryMolecular biologyTransplantationmedicine.anatomical_structureImmunologymedicinebiology.proteinStem cellAntigen-presenting cellBlood
researchProduct

Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.

2016

The hepatitis C virus (HCV) infected patients are prone to develop bone marrow or various tissue infiltrates with monoclonal B cells, monoclonal B lymphocytosis or different types of B cell non-Hodgkin's lymphoma (BCNHL), of which the most common are splenic marginal zone BCNHL, diffuse large BCNHL and follicular lymphoma. The association between chronic HCV infection and non Hodgkin's lymphoma has been observed especially in areas with high prevalence of this viral infection. Outside the limitations of some studies that have been conducted, there are also geographic, environmental, and genetic factors that contribute to the epidemiological differences. Various microenvironmental signals, s…

Lymphoma B-CellFollicular lymphomaAntineoplastic AgentsVirus ReplicationAntiviral Agents03 medical and health sciences0302 clinical medicinemedicineHumansLymphoma FollicularB cellCell ProliferationHepatitisB-Lymphocytesbusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsGastroenterologyHematopoietic Stem Cell TransplantationMinireviewsGeneral MedicineHepatitis CLymphoma B-Cell Marginal ZoneHepatitis BHepatitis C Chronicmedicine.diseaseLymphomaNon-Hodgkin's lymphomaLiver Transplantationmedicine.anatomical_structure030220 oncology & carcinogenesisImmunology030211 gastroenterology & hepatologyRituximabLymphoma Large B-Cell DiffuseHepatitis C AntigensbusinessRituximabmedicine.drugWorld journal of gastroenterology
researchProduct

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneum…

2019

Highlights • CMV DNA is frequently detected in BAL fluid specimens from allo-HSCT. • CMV DNA detection in BAL fluids is comparable across pneumonia etiologies. • CMV DNA loads in BAL fluids are comparable across pneumonia etiologies. • CMV DNA load in BAL may predict attributable-pneumonia mortality.

Male0301 basic medicineDna loadCMV pneumoniaCytomegalovirusmedicine.disease_causechemistry.chemical_compound0302 clinical medicinePre-emptive antiviral therapyMedicine030212 general & internal medicineCMV DNA in BALAged 80 and overmedicine.diagnostic_testHematopoietic Stem Cell Transplantationvirus diseasesrespiratory systemMiddle AgedViral LoadVirus SheddingInfectious DiseasesCytomegalovirus InfectionsFemaleAllogeneic hematopoietic stem cell transplantBronchoalveolar Lavage FluidAdultMicrobiology (medical)Pneumonia Viral030106 microbiologyCMV DNAemiaArticle03 medical and health sciencesHumansTransplantation HomologousAgedRetrospective Studiesbusiness.industryCMV PneumoniaCytomegalovirusRetrospective cohort studymedicine.diseaseTransplant Recipientsrespiratory tract diseasesPneumoniaBronchoalveolar lavagechemistryDNA ViralImmunologybusinessDNAJournal of Infection
researchProduct

Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?

2017

Abstract Background There is a lack of clinical information regarding the usefulness of plasma Epstein-Barr virus (EBV) DNA load kinetics analyses in the management of EBV infections in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Namely, it remains unknown whether this type of analysis can help physicians to anticipate the development of high-level EBV DNAemia episodes requiring rituximab treatment or predict the risk of recurrent EBV DNAemia or post-transplant lymphoproliferative disorders (PTLDs). Study design Unicentric, retrospective, observational study including 142 consecutive patients undergoing T-cell replete allo-HSCT. The plasma EBV DNA load was mon…

Male0301 basic medicineEpstein-Barr Virus InfectionsHerpesvirus 4 HumanDna loadmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationPolymerase Chain ReactionVirus03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicinehemic and lymphatic diseasesVirologyClinical informationHumansTransplantation HomologousMedicineRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationEpstein-Barr virus DNAvirus diseasesViral Loadmedicine.diseaseTransplant RecipientsKinetics030104 developmental biologyInfectious DiseasesDNA ViralImmunologyFemaleRituximabReagent Kits DiagnosticAllogeneic hematopoietic stem cell transplantRituximabbusiness030215 immunologymedicine.drugJournal of Clinical Virology
researchProduct

The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic s…

2018

Monitoring Torque teno virus (TTV) DNA load helps to estimate the risk of opportunistic infections in solid organ transplant recipients. We investigated whether the early kinetic pattern of plasma TTV DNA load after allogeneic hematopoietic stem cell transplantation (allo-HSCT) associates with subsequent CMV and EBV DNAemia. This study included 71 allo-HSCT patients. We found that the area under the curve (AUC) for log10 TTV DNA loads quantified by days 20 and 30 after transplantation (TTV DNA load AUC20-30), was significantly lower (P=0.036) in patients who subsequently developed CMV DNAemia requiring preemptive antiviral therapy (n=17) than in those who did not (n=8) or had no CMV DNAemia…

Male0301 basic medicineTorque teno virusTransplantation Conditioningmedicine.medical_treatment030106 microbiologyHematopoietic stem cell transplantation03 medical and health sciencesInterferonmedicineHumansRetrospective StudiesTorque teno virusTransplantationbusiness.industryHematopoietic Stem Cell TransplantationArea under the curvevirus diseasesHematologyCmv dnaemiaVirologyTransplantation030104 developmental biologyHematology; TransplantationCytomegalovirus InfectionsDNA ViralImmunologyFemaleTransplantation ConditioningbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality fr…

2018

Abstract Risk factors (RFs) and mortality data of community‐acquired respiratory virus (CARVs) lower respiratory tract disease (LRTD) with concurrent pulmonary co‐infections in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is scarce. From January 2011 to December 2017, we retrospectively compared the outcome of allo‐HSCT recipients diagnosed of CARVs LRTD mono‐infection (n = 52, group 1), to those with viral, bacterial, or fungal pulmonary CARVs LRTD co‐infections (n = 15, group 2; n = 20, group 3, and n = 11, group 4, respectively), and with those having bacterial pneumonia mono‐infection (n = 19, group 5). Overall survival (OS) at day 60 after bronchoalveol…

Male0301 basic medicinemedicine.medical_treatmentcommunity acquired respiratory virusHematopoietic stem cell transplantationBronchoalveolar LavageGastroenterology0302 clinical medicineRisk Factorsrespiratory virus co‐infectionsLungRespiratory Tract Infectionsmedicine.diagnostic_testRespiratory tract infectionsCoinfectionHematopoietic Stem Cell TransplantationMiddle AgedCommunity-Acquired InfectionsInfectious Diseasesmedicine.anatomical_structureVirusesvirus-bacterial mixed infectionsRespiratory virusFemaleOriginal Articlerespiratory virus co-infectionsBronchoalveolar Lavage FluidAdultmedicine.medical_specialtyvirus‐bacterial mixed infections030106 microbiologyContext (language use)CMV DNAemiaAntiviral Agents03 medical and health sciencesInternal medicinemedicineHumansTransplantation Homologousallogeneic hematopoietic stem cell transplantationAgedRetrospective StudiesTransplantationLungBacteriabusiness.industryFungiBacterial pneumoniaOriginal Articlesmedicine.diseaseTransplantationBronchoalveolar lavagebusinessimmunodeficiency score index030215 immunology
researchProduct

Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving or…

2015

Studies that analyze the epidemiology and risk factors for invasive fungal disease (IFD) after engraftment in alloSCT are few in number. This single-center retrospective study included 404 alloSCT adult recipients surviving > 40 days who engrafted and were discharged without prior IFD. All patients who received >= 20 mg/day of prednisone were assigned to primary oral prophylaxis (itraconazole or low-dose voriconazole). The primary end point was the cumulative incidence (CI) of probable/proven IFD using the European Organization for Research and Treatment of Cancer and Mycoses Study Group (EORTC/MSG) criteria. The independent prognostic factors after multivariate analyses were used to constr…

MaleAntifungal AgentsTransplantation ConditioningPremedicationmedicine.medical_treatmentMULTICENTERAdministration OralHematopoietic stem cell transplantationEchinocandinsCOMPETING RISKCaspofunginRisk FactorsCause of DeathINFECTIONGranulocyte Colony-Stimulating FactorEPIDEMIOLOGYCumulative incidenceTreatment FailureFramingham Risk ScoreIncidenceIncidence (epidemiology)Hematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsHematologic NeoplasmsVORICONAZOLEDrug Therapy CombinationFemaleASPERGILLOSISRisk assessmentFungemiamedicine.drugAdultmedicine.medical_specialtyNeutropeniaANTIFUNGAL PROPHYLAXISNeutropeniaRisk AssessmentITRACONAZOLEMedication AdherenceImmunocompromised HostLipopeptidesYoung AdultAmphotericin BInternal medicinemedicineAspergillosisHumansAgedRetrospective StudiesVoriconazoleTransplantationbusiness.industryRetrospective cohort studyFLUCONAZOLETriazolesmedicine.diseaseSurvival AnalysisSurgeryMycosesPatient CompliancebusinessSCT
researchProduct